Current Treatment of Nausea and Vomiting Associated with Gastroparesis: Antiemetics, Prokinetics, Tricyclics

Gastrointestinal Endoscopy Clinics of North America

Volumn 19, Issue 1, 2009, Pages 57-72

  Stapleton, Jeremy ^a   Wo, John M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Antiemetics; Gastroparesis; Nausea; Prokinetics; Tricyclics; Vomiting

Indexed keywords

ALCOHOL; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIMENHYDRINATE; DIPHENHYDRAMINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LORAZEPAM; MECLOZINE; MIDAZOLAM; MUSCARINIC RECEPTOR BLOCKING AGENT; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PLACEBO; PROCHLORPERAZINE MALEATE; PROKINETIC AGENT; PROMETHAZINE; SCOPOLAMINE; SEDATIVE AGENT; SEROTONIN 3 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACCOMMODATION DISORDER; ADJUVANT THERAPY; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY; BREAST HYPERTROPHY; BREAST TENDERNESS; CHRONIC DISEASE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHORIA; DYSTONIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HALLUCINATION; HEART ARREST; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; INJECTION SITE BURNING; INJECTION SITE PAIN; INSOMNIA; IRRITABLE COLON; LOW DRUG DOSE; NAUSEA AND VOMITING; NEUROMUSCULAR FUNCTION; NONCARDIAC CHEST PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARANOIA; PATHOPHYSIOLOGY; POSTOPERATIVE NAUSEA AND VOMITING; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SCAR FORMATION; SEDATION; SIDE EFFECT; STOMACH EMPTYING; STOMACH PARESIS; STOMACH SURGERY; SUDDEN DEATH; SYSTEMIC DISEASE; TARDIVE DYSKINESIA; TISSUE INJURY; TORSADE DES POINTES; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIEMETICS; DOPAMINE ANTAGONISTS; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROPARESIS; HUMANS; MOTILIN; NAUSEA; VOMITING;

EID: 68649091505     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2008.12.008     Document Type: Review

References (74)

1. Parkman H.P., Hasler W.L., and Fisher R.S. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterologist 127 5 (2004) 1592-1622
2. Wo J.M., and Parkman H.P. Diagnosis and management of functional dyspepsia and gastroparesis. Pract Gastroenterol 30 (2006) 3023-3048
3. De Block C.E., De Leeuw I.H., Pelckmans P.A., et al. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 25 5 (2002) 912-917
4. Jones K.L., Russo A., Stevens J.E., et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 24 7 (2001) 1264-1269
5. Maleki D., Locke III G.R., Camilleri M., et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 160 18 (2000) 2808-2816
6. Ricci J.A., Siddique R., Stewart W.F., et al. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. Scand J Gastroenterol 35 2 (2000) 152-159
7. Soykan I., Sivri B., Sarosiek I., et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 43 11 (1998) 2398-2404
8. Harrell S.P., Studts J.L., Dryden G.W., et al. A novel classification scheme for gastroparesis based on predominant-symptom presentation. Gastroenterologist 42 (2008) 455-459
9. Wang Y.R., Fisher R.S., and Parkman H.P. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol 103 2 (2008) 313-322
10. Quigley E.M., Hasler W.L., and Parkman H.P. AGA technical review on nausea and vomiting. Gastroenterologist 120 1 (2001) 263-286
11. Del F.A., Tonato M., and Roila F. Issues in the measurement of nausea. Br J Cancer 19 Suppl (1992) S69-S71
12. Hornby P.J. Central neurocircuitry associated with emesis. Am J Med 111 Suppl 8A (2001) 106S-112S
13. Sallan S.E., Cronin C., Zelen M., et al. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302 3 (1980) 135-138
14. Baloh R.W. Vertigo. Lancet 352 9143 (1998) 1841-1846
15. Wood C.D., Stewart J.J., Wood M.J., et al. Effectiveness and duration of intramuscular antimotion sickness medications. J Clin Pharmacol 32 11 (1992) 1008-1012
16. Pryse-Phillips W.E., Dodick D.W., Edmeads J.G., et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 156 9 (1997) 1273-1287
17. Skidmore F., and Reich S.G. Tardive dystonia. Curr Treat Options Neurol 7 3 (2005) 231-236
18. Severe tissue injury with IV promethazine. Available at:. http://www.accessdata.fda.gov/psn/transcript.cfm?show=58#6 Accessed August 24, 2008
19. Flake Z.A., Scalley R.D., and Bailey A.G. Practical selection of antiemetics. Am Fam Physician 69 5 (2004) 1169-1174
20. Ho K.Y., and Gan T.J. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 19 6 (2006) 606-611
21. Crucitt M.A., Hyman W., Grote T., et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 18 4 (1996) 778-788
22. Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21 22 (2003) 4112-4119
23. Grimsehl K., Whiteside J.B., and Mackenzie N. Comparison of cyclizine and ondansetron for the prevention of postoperative nausea and vomiting in laparoscopic day-case gynaecological surgery. Anaesthesia 57 1 (2002) 61-65
24. Johns R.A., Hanousek J., and Montgomery J.E. A comparison of cyclizine and granisetron alone and in combination for the prevention of postoperative nausea and vomiting. Anaesthesia 61 11 (2006) 1053-1057
25. Watcha M.F., and Smith I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth 6 5 (1994) 370-377
26. Navari R.M., and Koeller J.M. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 37 9 (2003) 1276-1286
27. Wood C.D., Manno J.E., Wood M.J., et al. Comparison of efficacy of ginger with various antimotion sickness drugs. Clin Res Pr Drug Regul Aff 6 2 (1988) 129-136
28. Nachum Z., Shupak A., and Gordon C.R. Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications. Clin Pharm 45 6 (2006) 543-566
29. Schmid R., Schick T., Steffen R., et al. Comparison of seven commonly used agents for prophylaxis of seasickness. J Travel Med 1 4 (1994) 203-206
30. McKeage K., Simpson D., and Wagstaff A.J. Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. Drugs 66 16 (2006) 2123-2147
31. Tramer M.R., and Walder B. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesth Analg 88 6 (1999) 1354-1361
32. Wang T.F., Liu Y.H., Chu C.C., et al. Low-dose haloperidol prevents post-operative nausea and vomiting after ambulatory laparoscopic surgery. Acta Anaesthesiol Scand 52 2 (2008) 280-284
33. FDA strengthens warnings for droperidol. Available at:. http://www.fda.gov/bbs/topics/answers/2001/ans01123.html Accessed August 24, 2008
34. Otsuka M., and Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73 2 (1993) 229-308
35. Navari R.M. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4 5 (2004) 715-724
36. Gan T.J., Apfel C.C., Kovac A., et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 104 5 (2007) 1082-1089 tables
37. Tramer M.R., Carroll D., Campbell F.A., et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 7303 (2001) 16-21
38. McCallum R.W., Valenzuela G., Polepalle S., et al. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 258 1 (1991) 136-142
39. Perkel M.S., Hersh T., Moore C., et al. Metoclopramide therapy in fifty-five patients with delayed gastric emptying. Am J Gastroenterol 74 3 (1980) 231-236
40. Snape Jr. W.J., Battle W.M., Schwartz S.S., et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 96 4 (1982) 444-446
41. McCallum R.W., Ricci D.A., Rakatansky H., et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 6 5 (1983) 463-467
42. Ricci D.A., Saltzman M.B., Meyer C., et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 7 1 (1985) 25-32
43. Lata P.F., and Pigarelli D.L. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 37 1 (2003) 122-126
44. Ganzini L., Casey D.E., Hoffman W.F., et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153 12 (1993) 1469-1475
45. Reddymasu S.C., Soykan I., and McCallum R.W. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102 9 (2007) 2036-2045
46. How to obtain domperidone?. Available at:. http://www.fda.gov/cder/news/domperidone.htm Accessed August 24, 2008
47. Lertxundi U., Peral J., Mora O., et al. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 65 5 (2008) 414-419
48. Farup C.E., Leidy N.K., Murray M., et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 21 10 (1998) 1699-1706
49. Silvers D., Kipnes M., Broadstone V., et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 20 3 (1998) 438-453
50. Patterson D., Abell T., Rothstein R., et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94 5 (1999) 1230-1234
51. Wo J.M., Woosley A., Eversmann J., et al. Open-label use of domperidone in patients with gastroparesis and small bowel dysfunction. [abstract]. Am J Gastroenterol 103 (2008) 546
52. Drolet B., Rousseau G., Daleau P., et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102 16 (2000) 1883-1885
53. Roussak J.B., Carey P., and Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 289 6458 (1984) 1579
54. Love E.M., Yin J.A., and Delamore I.W. Cardiotoxicity of intravenous domperidone. Lancet 2 8456 (1985) 676
55. Bruley d V., Parys V., Ropert A., et al. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterologist 109 1 (1995) 32-39
56. Cuomo R., Vandaele P., Coulie B., et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 101 4 (2006) 804-811
57. Bortolotti M., Mari C., Brunelli F., et al. Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Dig Dis Sci 44 12 (1999) 2439-2442
58. Sutera L., Dominguez L.J., Belvedere M., et al. Azithromycin in an older woman with diabetic gastroparesis. Am J Ther 15 1 (2008) 85-88
59. Tack J., Janssens J., Vantrappen G., et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterologist 103 1 (1992) 72-79
60. Desautels S.G., Hutson W.R., Christian P.E., et al. Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Dig Dis Sci 40 1 (1995) 141-146
61. Ehrenpreis E.D., Zaitman D., and Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmacokinetic analysis. Aliment Pharmacol Ther 12 4 (1998) 373-376
62. Annese V., Janssens J., Vantrappen G., et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterologist 102 3 (1992) 823-828
63. Janssens J., Peeters T.L., Vantrappen G., et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 322 15 (1990) 1028-1031
64. Kendall B.J., Chakravarti A., Kendall E., et al. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment Pharmacol Ther 11 2 (1997) 381-385
65. Dhir R., and Richter J.E. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol 38 3 (2004) 237-242
66. Richards R.D., Davenport K., and McCallum R.W. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 88 2 (1993) 203-207
67. Samsom M., Jebbink R.J., Akkermans L.M., et al. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 20 2 (1997) 129-134
68. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 11 (2004) 1089-1096
69. Jackson J.L., O'Malley P.G., Tomkins G., et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108 1 (2000) 65-72
70. Gorelick A.B., Koshy S.S., Hooper F.G., et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Phys 275 3 Pt 1 (1998) G460-G466
71. Namin F., Patel J., Lin Z., et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil 19 3 (2007) 196-202
72. Prakash C., and Clouse R.E. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 94 10 (1999) 2855-2860
73. Prakash C., Lustman P.J., Freedland K.E., et al. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 43 9 (1998) 1951-1956
74. Sawhney M.S., Prakash C., Lustman P.J., et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 52 2 (2007) 418-424